Search Results

AiCuris Anti-infective Cures AG announced that it has received milestone payments in the amount of EUR €15 million from its licensing partner MSD ) following EMA approval for the first-in-class antiviral agent PREVYMIS® for the prophylaxis of CMV disease after kidney transplant in Donor CMV-seropositive/Recipient CMV-seronegative patients at high risk.

AiCuris announced today that it has received milestone payments in the amount of EUR €30 million from its licensing partner MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA, (MRK)) following U.S. Food and Drug Administration (FDA) approval for first-in-class antiviral agent PREVYMIS ® in a new indication.

AiCuris Anti-infective Cures AG announced the opening of the third round of its AiCubator corporate innovation accelerator initiative.

AiCuris Anti-infective Cures AG, a leading clinical stage pharmaceutical company in the development of novel, resistance-breaking anti-infective agents for the treatment of severe and potentially life-threatening infectious diseases, announced the appointment of Larry Edwards as Chief Executive Officer, effective April 1, 2023.

AiCuris Anti-infective Cures AG, a leading company in the discovery and development of drugs against infectious diseases, announced the appointment of Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer, effective September 1, 2022.

AiCuris Anti-infective Cures AG, a leading company in the discovery and development of drugs against infectious diseases, announced that the Supervisory Board appointed Dr. Stefan Oschmann as chairman.

AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of drugs against infectious diseases, announced that the Company’s shareholder resolved to change the legal form from the German “GmbH” to a stock corporation.

AiCuris acquires exclusive rights to develop and commercialize Hybridize’s program to prevent severe disease from BK virus (BKV) infections in immunocompromised patients.

AiCuris Anti-infective Cures AG, a leading company in the discovery and development of drugs against infectious diseases, and the biotechnology company Lysando AG with its Regensburg-based subsidiary Lysando GmbH, announced the expansion of their existing long-term collaboration for the development and optimization of Artilysin-based drug candidates for the topical treatment of infected, chronic wounds such as diabetic foot infections.